Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · PMV Pharmaceuticals, Inc. (PMVP)

PMV Pharma appoints Matthew Eckler, Ph.D., to board of directors

Neutral Impact 2 of 5 leadership Written later

PMV Pharmaceuticals appointed Dr. Matthew Eckler, a Principal at Samsara BioCapital, to its Board of Directors effective October 1, 2026. The filing describes a routine board addition with standard non-employee director compensation, and it notes the company plans to submit an NDA for accelerated approval of rezatapopt in the first quarter of 2027.

Key points

  • Dr. Eckler's board term expires at the 2029 Annual Meeting of Stockholders; appointment date October 1, 2026.
  • Annual cash retainer of $40,000 plus additional cash pay for committee service.
  • Initial stock option award for 84,000 shares; expected annual option for 42,000 shares at each annual meeting.
  • Company plans to submit an NDA for rezatapopt in platinum-resistant/refractory ovarian cancer in Q1 2027.

The filing

CompanyPMV Pharmaceuticals, Inc. (PMVP)
Form8-K, current report
Filed with the SECOct 5, 2026, 9:00 AM ET
Accession number0001193125-26-413254

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.